Business Context and Reporting Period
Company: Ekso Bionics Holdings, Inc. (Ticker: EKSO)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Designs and markets exoskeleton technology for healthcare (neurorehabilitation) and industrial markets. The company is currently pursuing a business combination with Applied Digital Cloud Corporation (ChronoScale), which, if consummated, will result in a name change to ChronoScale Corporation and a fiscal year-end change to May 31.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $2.14 million | $3.38 million |
| Gross Profit | $1.07 million | $1.81 million |
| Gross Margin | 50% | 54% |
| Net Loss | $(6.89) million | $(2.89) million |
| Net Loss Per Share (Basic/Diluted) | $(2.04) | $(1.84) |
| Cash and Restricted Cash | $4.0 million | $8.05 million |
| Working Capital | $5.0 million | $5.4 million |
| Total Debt (Current + Non-Current) | ~$4.85 million | ~$4.0 million |
Note: Debt includes B. Riley Promissory Note ($2.08M), Parker Hannifin Note ($1.77M), and other notes/leases.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 37% year-over-year, driven by lower volume in Enterprise Health device sales across all regions (Americas, EMEA, APAC).
- Increased Operating Expenses: Total operating expenses rose 28% to $6.69 million. General and Administrative (G&A) expenses increased 59% primarily due to legal costs associated with the proposed Business Combination. Sales and Marketing expenses increased 20% due to higher bad debt expense ($0.3 million) from a single counterparty.
- Warrant Liability Revaluation: The company recorded a $0.73 million loss on the revaluation of warrant liabilities, compared to a negligible gain in the prior year. This is a non-cash charge driven by changes in stock price and volatility.
- Foreign Exchange: Unrealized foreign exchange loss of $0.24 million in Q1 2026, compared to a gain of $0.63 million in Q1 2025.
- Financing Activity: In January 2026, the company completed a private placement raising net proceeds of approximately $5.3 million via Series B Convertible Preferred Stock and warrants.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for 12 months from the filing date. Cash on hand is estimated to fund operations only into the early part of Q3 2026. Additional financing is required.
- Business Combination: The proposed merger with Applied Digital Cloud is subject to conditions, including raising at least $15 million in cash. If the deal fails, the company faces significant liquidity risks and potential dilution from future fundraising.
- Revenue Strategy: Management expects 2026 revenue to remain primarily driven by Enterprise Health sales, with Personal Health (Ekso Indego Personal) contributing incrementally as Medicare reimbursement processes are refined.
- Cost Reduction: The company is pursuing cost reduction efforts, delaying product development, and refocusing sales to align expenses with available cash, though success is not guaranteed.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next financing round given the "early Q3 2026" cash runway estimate.
- Business Combination Status: Monitor progress on the $15 million cash condition and regulatory approvals for the Applied Digital Cloud merger.
- Bad Debt Exposure: Assess the collectability of the specific customer account that triggered the $0.3 million bad debt charge.
- Warrant Liability Volatility: Review the impact of stock price fluctuations on the recurring non-cash warrant liability revaluation charges.
- Debt Covenants: Confirm compliance with covenants on the B. Riley Promissory Note (due Sept 2026) and Parker Hannifin Note.